Anti	O
-	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
-	O
beta	O
antibodies	O
inhibit	O
breast	B-Cell
cancer	I-Cell
cell	I-Cell
tumorigenicity	O
and	O
increase	O
mouse	O
spleen	B-Cell
natural	I-Cell
killer	I-Cell
cell	I-Cell
activity	O
.	O

Implications	O
for	O
a	O
possible	O
role	O
of	O
tumor	B-Cell
cell	I-Cell
/	O
host	O
TGF	O
-	O
beta	O
interactions	O
in	O
human	O
breast	B-Cancer
cancer	I-Cancer
progression	O
.	O

TGF	O
-	O
beta	O
effects	O
on	O
angiogenesis	O
,	O
stroma	B-Tissue
formation	O
,	O
and	O
immune	O
function	O
suggest	O
its	O
possible	O
involvement	O
in	O
tumor	B-Cancer
progression	O
.	O

This	O
hypothesis	O
was	O
tested	O
using	O
the	O
2G7	O
IgG2b	O
,	O
which	O
neutralizes	O
TGF	O
-	O
beta	O
1	O
,	O
-	O
beta	O
2	O
,	O
and	O
-	O
beta	O
3	O
,	O
and	O
the	O
MDA	B-Cell
-	I-Cell
231	I-Cell
human	O
breast	B-Cell
cancer	I-Cell
cell	I-Cell
line	I-Cell
.	O

Inoculation	O
of	O
these	O
cells	B-Cell
in	O
athymic	O
mice	O
decreases	O
mouse	O
spleen	B-Cell
natural	I-Cell
killer	I-Cell
(	I-Cell
NK	I-Cell
)	I-Cell
cell	I-Cell
activity	O
.	O

Intraperitoneal	B-Immaterial_anatomical_entity
injections	O
of	O
2G7	O
starting	O
1	O
d	O
after	O
intraperitoneal	B-Immaterial_anatomical_entity
inoculation	O
of	O
tumor	B-Cell
cells	I-Cell
suppressed	O
intraabdominal	B-Cancer
tumor	I-Cancer
and	O
lung	B-Cancer
metastases	I-Cancer
,	O
whereas	O
the	O
nonneutralizing	O
anti	O
-	O
TGF	O
-	O
beta	O
12H5	O
IgG2a	O
had	O
no	O
effect	O
.	O

2G7	O
transiently	O
inhibited	O
growth	O
of	O
established	O
MDA	B-Cancer
-	I-Cancer
231	I-Cancer
subcutaneous	I-Cancer
tumors	I-Cancer
.	O

Histologically	O
,	O
both	O
2G7	O
-	O
treated	O
and	O
control	O
tumors	B-Cancer
were	O
identical	O
.	O

Intraperitoneal	B-Immaterial_anatomical_entity
administration	O
of	O
2G7	O
resulted	O
in	O
a	O
marked	O
increase	O
in	O
mouse	O
spleen	B-Cell
NK	I-Cell
cell	I-Cell
activity	O
.	O

2G7	O
did	O
not	O
inhibit	O
MDA	B-Cancer
-	I-Cancer
231	I-Cancer
primary	I-Cancer
tumor	I-Cancer
or	O
metastases	B-Cancer
formation	O
,	O
nor	O
did	O
it	O
stimulate	O
NK	B-Cell
cell	I-Cell
-	O
mediated	O
cytotoxicity	O
in	O
beige	O
NK	O
-	O
deficient	O
nude	O
mice	O
.	O

Finally	O
,	O
serum	B-Organism_substance
-	O
free	O
conditioned	O
medium	O
from	O
MDA	B-Cell
-	I-Cell
231	I-Cell
cells	I-Cell
inhibited	O
the	O
NK	B-Cell
cell	I-Cell
activity	O
of	O
human	O
blood	B-Cell
lymphocytes	I-Cell
.	O

This	O
inhibition	O
was	O
blocked	O
by	O
the	O
neutralizing	O
anti	O
-	O
TGF	O
-	O
beta	O
2G7	O
antibody	O
but	O
not	O
by	O
a	O
nonspecific	O
IgG2	O
.	O

These	O
data	O
support	O
a	O
possible	O
role	O
for	O
tumor	B-Cell
cell	I-Cell
TGF	O
-	O
beta	O
in	O
the	O
progression	O
of	O
mammary	B-Cancer
carcinomas	I-Cancer
by	O
suppressing	O
host	O
immune	O
surveillance	O
.	O

